company background image
BOLT logo

BioLight Life Sciences TASE:BOLT Stock Report

Last Price

₪6.89

Market Cap

₪32.1m

7D

4.8%

1Y

37.8%

Updated

06 Feb, 2025

Data

Company Financials

BioLight Life Sciences Ltd.

TASE:BOLT Stock Report

Market Cap: ₪32.1m

BOLT Stock Overview

An ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. More details

BOLT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

BioLight Life Sciences Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BioLight Life Sciences
Historical stock prices
Current Share Price₪6.89
52 Week High₪6.92
52 Week Low₪3.34
Beta0.58
1 Month Change7.56%
3 Month Change56.17%
1 Year Change37.80%
3 Year Change-38.70%
5 Year Change-23.77%
Change since IPO-98.33%

Recent News & Updates

Recent updates

Shareholder Returns

BOLTIL Life SciencesIL Market
7D4.8%4.1%2.9%
1Y37.8%24.2%34.5%

Return vs Industry: BOLT exceeded the IL Life Sciences industry which returned 19.8% over the past year.

Return vs Market: BOLT exceeded the IL Market which returned 34.4% over the past year.

Price Volatility

Is BOLT's price volatile compared to industry and market?
BOLT volatility
BOLT Average Weekly Movement9.3%
Life Sciences Industry Average Movement6.6%
Market Average Movement4.6%
10% most volatile stocks in IL Market9.1%
10% least volatile stocks in IL Market3.1%

Stable Share Price: BOLT's share price has been volatile over the past 3 months compared to the IL market.

Volatility Over Time: BOLT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of IL stocks.

About the Company

FoundedEmployeesCEOWebsite
20054Yaacov Michlinbio-light.co.il

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company’s ophthalmic product offering and pipeline of product candidates include DiagnosTear’s TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma.

BioLight Life Sciences Ltd. Fundamentals Summary

How do BioLight Life Sciences's earnings and revenue compare to its market cap?
BOLT fundamental statistics
Market cap₪32.09m
Earnings (TTM)-₪6.16m
Revenue (TTM)₪198.00k

162.1x

P/S Ratio

-5.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BOLT income statement (TTM)
Revenue₪198.00k
Cost of Revenue₪0
Gross Profit₪198.00k
Other Expenses₪6.36m
Earnings-₪6.16m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.32
Gross Margin100.00%
Net Profit Margin-3,109.60%
Debt/Equity Ratio0%

How did BOLT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 08:53
End of Day Share Price 2025/02/06 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioLight Life Sciences Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pooya HemamiEdison Investment Research
Brian MurphyMerriman Capital, Inc
Brian MarckxZacks Investment Research Inc.